comprehensive -WSS

comprehensive

author：knowledge 2025-09-02 11:46:48 - browse：6828

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Report: NIH

leisure time

WSS

Average age of first period drops to 11.9 years, study shows

Black vets could get higher VA benefits if race not used in lung test

Crowdfunding for medical bills sidesteps core problem, author says

Lawmakers grill UnitedHealth CEO on Change cyberattack

Brain technologies pose threats that are all too real, experts warn

Crowdfunding for medical bills sidesteps core problem, author says

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Heart attack and stroke risk calculators need revising

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

The high cost of giving birth even with insurance

Do more moles mean more problems? Not so, says new study

Affirmative action in medical school literally saved lives

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Bright Health sells Medicare Advantage business to Molina

Antibiotic resistance nearly killed me, so I'm raising awareness of it

At least 13 dead in Texas as scorching temps continue

PBM executives asked to testify by House panel

explore

HHS's proposed rule does nothing to address the climate crisis

AI for drug discovery: Experts on separating hype from reality

First Opinion Podcast: What happens when kids become caregivers?

HHS's proposed rule does nothing to address the climate crisis

Welsh Carson private equity firm escapes from FTC antitrust case

Health insurers say they are turning to AI to cut costs, improve care

focus

Wikipedia

leisure time

explore